SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Ligand Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) ("Ligand") concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On November 3, 2016, Ligand announced it was evaluating certain deferred tax assets recorded in the third quarter of 2015. On November 9, 2016, Ligand announced that the Company would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and was determining whether restatement would be necessary. Then on November 14, 2016, post-market, Ligand announced that the Company would restate financial statements for the quarters ended September 30, 2015, December 31, 2015, March 31, 2016, and June 30, 2016, due to a material error. According to Ligand, "the Company did not maintain effective controls over the accuracy and presentation of the accounting for income taxes relate[d] to complex transactions, including the income tax provision and related tax assets and liabilities and controls over the financial reporting classification of convertible debt and temporary equity." To obtain additional information, go to:

http://zlk.9nl.com/ligand-pharmaceuticals

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161115006355/en/
Copyright Business Wire 2010

If you liked this article you might like

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More